Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Inclusion Criteria: * Patient has histologically proven stage IIIB with pleural effusion, stage IV or recurrent non-squamous NSCLC. * Patient has a Karnofsky performance status \>=70%. * Patient has adequate bone marrow function: WBC \>= 3,000 cells/mm3, ANC \>= 1,500 cells/mm3, platelet count \>= 100,000 cells/mm3, Hgb \>= 9.0 g/dL. * Patient has adequate liver function: total bilirubin level \<= 2.0 mg/dL, albumin \>= 2.5 g/dL. * Transaminases (aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT)) and alkaline phosphatase may be up to 2.5 x ULN. * Patient has adequate renal function: a serum creatinine \< 2 mg/dl * Patient has signed a written informed consent. * Patient has received at least one prior chemotherapeutic regimen for recurrent or metastatic disease. Exclusion Criteria: * Patient has not received prior chemotherapeutic regimens for advanced disease. * Patient has received prior biologic therapy targeting epidermal growth factor receptor (EGFR) and/or Vascular endothelial growth factor (VEGF). * Patient has received radiation therapy within the past 3 weeks. * Patient has signs or symptoms of acute infection requiring systemic therapy. * Patient exhibits confusion, disorientation, or has a history of major psychiatric illness that may impair patient's understanding of the informed consent. * Patient requires total parenteral nutrition with lipids. * Patient has a history of uncontrolled heart disease and/or uncontrolled hypertension (\> 150/100 mmHg). * Because of the possible teratogenic effect, pregnant women and women who are currently breast-feeding may not participate in this study. - All women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrolling in the study. * Serious infection or other intercurrent illness requiring immediate therapy. * Clinical/imaging evidence of Central Nervous System (CNS) malignancy or with recently treated CNS malignancy, as well as those experiencing recent cerebrovascular accident (CVA), or other CNS bleeding. * Pediatric patients in whom open growth plates would be expected. * Urine protein qualitative value of \> 30 in urinalysis or \> +1 in proteinuria testing by dipstick. * Patient has a clinical history of coagulopathy or thrombosis. * Patient is currently receiving or intending to receive anti-coagulants. * Patient has had a recent myocardial infarction (still inside the healing period). Note: a six-month window is optimal. * Patient is recovering from recent major surgery (e.g., less than 2 weeks since surgery) or is anticipating major surgery. * Patient has a clinical history of hemoptysis or hematemesis. * Patient may not have percutaneous endoscopic gastrostomy (PEG) or gastrostomy (G) tube.